Tonix Pharmaceuticals Holding Corp
Sep 5, 2019
Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) President and CEO Seth Lederman tells Proactive the New York-based biopharma has begun dosing patients suffering from post-traumatic stress disorder in a Phase 1 study with its daytime therapy TNX-601. Lederman says TNX-601 is one of three drug candidates the company is developing for PTSD, with its most advanced being TNX-102 SL, currently in Phase 3 development.
Sep 5, 2019
Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) President and CEO Seth Lederman tells Proactive the New York-based biopharma has begun dosing patients suffering from post-traumatic stress disorder in a Phase 1 study with its daytime therapy TNX-601. Lederman says TNX-601 is one of three drug candidates the company is developing for PTSD, with its most advanced being TNX-102 SL, currently in Phase 3 development.